Why Teleflex is Back on Investors’ Radar
Teleflex (TFX) has attracted renewed attention after recent share price moves, with the stock up over the past month but lower over the past 3 months and year to date.
See our latest analysis for Teleflex.
Teleflex’s recent 1 month share price return of 1.94% sits against a weaker backdrop, with a 3 month share price return showing an 8.71% decline and a 1 year total shareholder return reflecting an 8.10% loss, suggesting momentum has been fading rather than building.
If you are comparing Teleflex with other medical and technology focused names, this is a good moment to scan for opportunities in 37 healthcare AI stocks
With the share price weaker over 3 and 12 months but Teleflex trading at what looks like a roughly 45% intrinsic discount, you have to ask: is this a genuine entry point, or is the market already pricing in future growth?
Most Popular Narrative: 11% Undervalued
Teleflex’s fair value in the widely followed narrative sits at $129.25 compared with a last close of $115.51, putting a spotlight on the underlying assumptions behind that gap.
The company's focus on portfolio optimization and potential separation or sale of business segments (e.g., NewCo), with anticipated proceeds deployed for debt paydown and shareholder returns, could unlock value and increase net margins and EPS through a more focused, streamlined operating model.
Read the complete narrative. Read the complete narrative.
Want to understand why a business with modest revenue growth assumptions still lands at a higher fair value? The narrative focuses on richer profit margins, a different future earnings multiple, and what happens if those margin and multiple assumptions intersect at the same time. The full breakdown shows how those moving pieces fit together, and how sensitive that $129.25 figure is to even small shifts in earnings power.
Result: Fair Value of $129.25 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that fair value gap depends on UroLift weakness easing and the BIOTRONIK acquisition integrating smoothly, and either issue could quickly challenge the bullish narrative.
Find out about the key risks to this Teleflex narrative.
Another Angle on Teleflex’s Valuation
There is a tension between the narrative fair value of $129.25 and what the P/E numbers are signaling. Teleflex trades on an 87.2x P/E, compared with 26.7x for the US Medical Equipment industry and a fair ratio of 35.2x, which points to valuation risk rather than a clear bargain. This raises the question of whether the discount story is already reflected in an expensive earnings multiple.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages in the story so far? Take a moment to review the data for yourself, weigh both sides, and see how the 2 key rewards and 2 important warning signs fits your view.
Ready for More Investment Ideas?
If Teleflex has piqued your interest, do not stop here. Broader, high quality ideas could be just a few filters away, and missing them could cost you opportunities.
- Zero in on potential value opportunities by scanning 61 high quality undervalued stocks with proven balance sheets and cash flows.
- Prioritise resilience and sleep a little easier at night by focusing on companies in the 70 resilient stocks with low risk scores.
- Hunt for potential future standouts that the market may be overlooking with the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com